comparemela.com

Latest Breaking News On - Yong cang - Page 1 : comparemela.com

Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue Degraders

Collaboration will leverage Degron's GlueXplorer® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation Degron will receive upfront payment and

Chris arendtDegron gluexplorerYong cangLily zouShanghaitech universityHead of researchDegron therapeuticsChief scientific officer

Takeda gets crafty with molecular glue deal worth $1 2B biobucks

Takeda has taken a trip all the way to Shanghai to find just the right kind of glue to stick together a $1.2 billion biobucks deal for new candidates.

Takeda chris arendtOrionis biosciencesDegron gluexplorerYong cangShanghaitech universityNovo nordiskDegron therapeuticsChris arendt

Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability of PD-1 antibodySAN DIEGO and SHANGHAI, June 2.

Lily zouYong cangNational natural science foundation of chinaShanghaitech universityShanghaitech university school of life scienceTechnology commissionCell chemical biologyLife scienceNational natural science foundationShanghai science

China Digest: 3D printing firm HBD raises $45m; biotech startup Degron closes $22m

HBD’s Series C round was led by China Life Private Equity Investment

Jing yuLily zouYong cangShanghaitech universityChina iron steel research instituteNuclear power institute of chinaChina life private equity investmentDegron therapeuticsChina life private equityZhongshan cityGuangdong provinceGree electricChina ironSteel research instituteNuclear power instituteLife private equity investment

Degron Therapeutics Raises $22M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

San diegoUnited statesJing yuLily zouYong cangShanghaitech universityDegron therapeuticsMed fine capitalDyee capitalBaidu ventureNeux capitalYuanbio venture

vimarsana © 2020. All Rights Reserved.